nodes	percent_of_prediction	percent_of_DWPC	metapath
Roflumilast—PDE4A—chronic obstructive pulmonary disease	0.57	1	CbGaD
Roflumilast—PDE4A—Aminophylline—chronic obstructive pulmonary disease	0.315	1	CbGbCtD
Roflumilast—PDE4C—DARPP-32 events—PDE4A—chronic obstructive pulmonary disease	0.00128	0.117	CbGpPWpGaD
Roflumilast—PDE4D—DARPP-32 events—PDE4A—chronic obstructive pulmonary disease	0.00112	0.102	CbGpPWpGaD
Roflumilast—PDE4B—DARPP-32 events—PDE4A—chronic obstructive pulmonary disease	0.000985	0.0895	CbGpPWpGaD
Roflumilast—PDE4C—Opioid Signalling—PDE4A—chronic obstructive pulmonary disease	0.000518	0.047	CbGpPWpGaD
Roflumilast—PDE4C—G Protein Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000463	0.0421	CbGpPWpGaD
Roflumilast—PDE4D—Opioid Signalling—PDE4A—chronic obstructive pulmonary disease	0.000451	0.0409	CbGpPWpGaD
Roflumilast—PDE4D—G Protein Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000403	0.0367	CbGpPWpGaD
Roflumilast—PDE4B—Opioid Signalling—PDE4A—chronic obstructive pulmonary disease	0.000397	0.0361	CbGpPWpGaD
Roflumilast—Connective tissue disorder—Formoterol—chronic obstructive pulmonary disease	0.000389	0.00377	CcSEcCtD
Roflumilast—Connective tissue disorder—Arformoterol—chronic obstructive pulmonary disease	0.000389	0.00377	CcSEcCtD
Roflumilast—Rhinitis—Montelukast—chronic obstructive pulmonary disease	0.000389	0.00377	CcSEcCtD
Roflumilast—Anxiety—Aminophylline—chronic obstructive pulmonary disease	0.000385	0.00372	CcSEcCtD
Roflumilast—Connective tissue disorder—Montelukast—chronic obstructive pulmonary disease	0.000381	0.00369	CcSEcCtD
Roflumilast—Palpitations—Tiotropium—chronic obstructive pulmonary disease	0.000378	0.00366	CcSEcCtD
Roflumilast—Rhinitis—Salbutamol—chronic obstructive pulmonary disease	0.000375	0.00363	CcSEcCtD
Roflumilast—Endocrine disorder—Prednisone—chronic obstructive pulmonary disease	0.000375	0.00363	CcSEcCtD
Roflumilast—PDE4C—G alpha (s) signalling events—PDE4A—chronic obstructive pulmonary disease	0.000368	0.0334	CbGpPWpGaD
Roflumilast—Cardiac disorder—Formoterol—chronic obstructive pulmonary disease	0.000368	0.00356	CcSEcCtD
Roflumilast—Cardiac disorder—Arformoterol—chronic obstructive pulmonary disease	0.000368	0.00356	CcSEcCtD
Roflumilast—Connective tissue disorder—Salbutamol—chronic obstructive pulmonary disease	0.000368	0.00356	CcSEcCtD
Roflumilast—Infection—Aminophylline—chronic obstructive pulmonary disease	0.000368	0.00356	CcSEcCtD
Roflumilast—Myalgia—Tiotropium—chronic obstructive pulmonary disease	0.000364	0.00352	CcSEcCtD
Roflumilast—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.000363	0.00351	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.000361	0.0035	CcSEcCtD
Roflumilast—Cardiac disorder—Montelukast—chronic obstructive pulmonary disease	0.00036	0.00349	CcSEcCtD
Roflumilast—Immune system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000358	0.00346	CcSEcCtD
Roflumilast—Immune system disorder—Formoterol—chronic obstructive pulmonary disease	0.000358	0.00346	CcSEcCtD
Roflumilast—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000357	0.00346	CcSEcCtD
Roflumilast—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000357	0.00346	CcSEcCtD
Roflumilast—PDE4B—G Protein Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000355	0.0323	CbGpPWpGaD
Roflumilast—Immune system disorder—Montelukast—chronic obstructive pulmonary disease	0.000351	0.00339	CcSEcCtD
Roflumilast—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00035	0.00339	CcSEcCtD
Roflumilast—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.000347	0.00336	CcSEcCtD
Roflumilast—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.000347	0.00336	CcSEcCtD
Roflumilast—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.000347	0.00336	CcSEcCtD
Roflumilast—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000347	0.00335	CcSEcCtD
Roflumilast—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.000345	0.00334	CcSEcCtD
Roflumilast—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.000345	0.00334	CcSEcCtD
Roflumilast—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.000342	0.00331	CcSEcCtD
Roflumilast—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.00034	0.00329	CcSEcCtD
Roflumilast—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000339	0.00328	CcSEcCtD
Roflumilast—Tension—Formoterol—chronic obstructive pulmonary disease	0.000339	0.00328	CcSEcCtD
Roflumilast—Tension—Arformoterol—chronic obstructive pulmonary disease	0.000339	0.00328	CcSEcCtD
Roflumilast—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000338	0.00327	CcSEcCtD
Roflumilast—Dysgeusia—Arformoterol—chronic obstructive pulmonary disease	0.000338	0.00327	CcSEcCtD
Roflumilast—Dysgeusia—Formoterol—chronic obstructive pulmonary disease	0.000338	0.00327	CcSEcCtD
Roflumilast—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000337	0.00326	CcSEcCtD
Roflumilast—Nervousness—Arformoterol—chronic obstructive pulmonary disease	0.000335	0.00324	CcSEcCtD
Roflumilast—Nervousness—Formoterol—chronic obstructive pulmonary disease	0.000335	0.00324	CcSEcCtD
Roflumilast—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.000335	0.00324	CcSEcCtD
Roflumilast—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.000334	0.00323	CcSEcCtD
Roflumilast—Back pain—Formoterol—chronic obstructive pulmonary disease	0.000334	0.00323	CcSEcCtD
Roflumilast—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.000332	0.00321	CcSEcCtD
Roflumilast—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.000332	0.00321	CcSEcCtD
Roflumilast—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.000328	0.00317	CcSEcCtD
Roflumilast—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.000326	0.00315	CcSEcCtD
Roflumilast—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000326	0.00315	CcSEcCtD
Roflumilast—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.000325	0.00314	CcSEcCtD
Roflumilast—Tremor—Formoterol—chronic obstructive pulmonary disease	0.000323	0.00313	CcSEcCtD
Roflumilast—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.000323	0.00313	CcSEcCtD
Roflumilast—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000322	0.00311	CcSEcCtD
Roflumilast—PDE4D—G alpha (s) signalling events—PDE4A—chronic obstructive pulmonary disease	0.00032	0.0291	CbGpPWpGaD
Roflumilast—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	0.00032	0.0031	CcSEcCtD
Roflumilast—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	0.00032	0.0031	CcSEcCtD
Roflumilast—Tension—Salbutamol—chronic obstructive pulmonary disease	0.00032	0.00309	CcSEcCtD
Roflumilast—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.000319	0.00309	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000318	0.00308	CcSEcCtD
Roflumilast—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000317	0.00306	CcSEcCtD
Roflumilast—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.000316	0.00306	CcSEcCtD
Roflumilast—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000316	0.00305	CcSEcCtD
Roflumilast—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000315	0.00305	CcSEcCtD
Roflumilast—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000315	0.00305	CcSEcCtD
Roflumilast—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.000315	0.00305	CcSEcCtD
Roflumilast—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000313	0.00303	CcSEcCtD
Roflumilast—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.000311	0.00301	CcSEcCtD
Roflumilast—Malaise—Formoterol—chronic obstructive pulmonary disease	0.000311	0.00301	CcSEcCtD
Roflumilast—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000309	0.00299	CcSEcCtD
Roflumilast—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000307	0.00297	CcSEcCtD
Roflumilast—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000305	0.00295	CcSEcCtD
Roflumilast—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000305	0.00295	CcSEcCtD
Roflumilast—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000305	0.00295	CcSEcCtD
Roflumilast—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000303	0.00293	CcSEcCtD
Roflumilast—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.000302	0.00292	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000301	0.00291	CcSEcCtD
Roflumilast—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000299	0.00289	CcSEcCtD
Roflumilast—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000298	0.00289	CcSEcCtD
Roflumilast—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000298	0.00288	CcSEcCtD
Roflumilast—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000294	0.00284	CcSEcCtD
Roflumilast—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000294	0.00284	CcSEcCtD
Roflumilast—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000294	0.00284	CcSEcCtD
Roflumilast—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000294	0.00284	CcSEcCtD
Roflumilast—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000293	0.00283	CcSEcCtD
Roflumilast—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000293	0.00283	CcSEcCtD
Roflumilast—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.000293	0.00283	CcSEcCtD
Roflumilast—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000292	0.00283	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000292	0.00282	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000292	0.00282	CcSEcCtD
Roflumilast—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.00029	0.00281	CcSEcCtD
Roflumilast—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00029	0.00281	CcSEcCtD
Roflumilast—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000288	0.00279	CcSEcCtD
Roflumilast—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000288	0.00278	CcSEcCtD
Roflumilast—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000287	0.00277	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000286	0.00276	CcSEcCtD
Roflumilast—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000285	0.00276	CcSEcCtD
Roflumilast—PDE4B—G alpha (s) signalling events—PDE4A—chronic obstructive pulmonary disease	0.000282	0.0256	CbGpPWpGaD
Roflumilast—Infection—Arformoterol—chronic obstructive pulmonary disease	0.00028	0.00271	CcSEcCtD
Roflumilast—Infection—Formoterol—chronic obstructive pulmonary disease	0.00028	0.00271	CcSEcCtD
Roflumilast—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000277	0.00268	CcSEcCtD
Roflumilast—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000277	0.00268	CcSEcCtD
Roflumilast—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000276	0.00267	CcSEcCtD
Roflumilast—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000276	0.00267	CcSEcCtD
Roflumilast—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000276	0.00267	CcSEcCtD
Roflumilast—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000276	0.00267	CcSEcCtD
Roflumilast—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000274	0.00265	CcSEcCtD
Roflumilast—Infection—Montelukast—chronic obstructive pulmonary disease	0.000274	0.00265	CcSEcCtD
Roflumilast—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000273	0.00265	CcSEcCtD
Roflumilast—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000273	0.00265	CcSEcCtD
Roflumilast—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000273	0.00264	CcSEcCtD
Roflumilast—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.00027	0.00262	CcSEcCtD
Roflumilast—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000268	0.00259	CcSEcCtD
Roflumilast—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000264	0.00256	CcSEcCtD
Roflumilast—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000261	0.00252	CcSEcCtD
Roflumilast—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000258	0.0025	CcSEcCtD
Roflumilast—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000257	0.00249	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000257	0.00248	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000257	0.00248	CcSEcCtD
Roflumilast—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000255	0.00246	CcSEcCtD
Roflumilast—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000255	0.00246	CcSEcCtD
Roflumilast—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000253	0.00245	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000251	0.00243	CcSEcCtD
Roflumilast—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000249	0.00241	CcSEcCtD
Roflumilast—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000248	0.0024	CcSEcCtD
Roflumilast—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000248	0.0024	CcSEcCtD
Roflumilast—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000245	0.00237	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000243	0.00235	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000243	0.00235	CcSEcCtD
Roflumilast—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000243	0.00235	CcSEcCtD
Roflumilast—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000243	0.00235	CcSEcCtD
Roflumilast—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000243	0.00235	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000242	0.00234	CcSEcCtD
Roflumilast—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000241	0.00233	CcSEcCtD
Roflumilast—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000241	0.00233	CcSEcCtD
Roflumilast—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.00024	0.00233	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000238	0.0023	CcSEcCtD
Roflumilast—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000238	0.0023	CcSEcCtD
Roflumilast—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000235	0.00228	CcSEcCtD
Roflumilast—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000234	0.00226	CcSEcCtD
Roflumilast—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000233	0.00226	CcSEcCtD
Roflumilast—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000233	0.00225	CcSEcCtD
Roflumilast—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000232	0.00225	CcSEcCtD
Roflumilast—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000232	0.00225	CcSEcCtD
Roflumilast—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000232	0.00224	CcSEcCtD
Roflumilast—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000231	0.00224	CcSEcCtD
Roflumilast—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000231	0.00223	CcSEcCtD
Roflumilast—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.00023	0.00223	CcSEcCtD
Roflumilast—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.00023	0.00223	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00023	0.00222	CcSEcCtD
Roflumilast—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000229	0.00222	CcSEcCtD
Roflumilast—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000227	0.0022	CcSEcCtD
Roflumilast—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000226	0.00218	CcSEcCtD
Roflumilast—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000224	0.00216	CcSEcCtD
Roflumilast—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000224	0.00216	CcSEcCtD
Roflumilast—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000223	0.00215	CcSEcCtD
Roflumilast—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000223	0.00215	CcSEcCtD
Roflumilast—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000222	0.00215	CcSEcCtD
Roflumilast—Rash—Tiotropium—chronic obstructive pulmonary disease	0.00022	0.00213	CcSEcCtD
Roflumilast—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.00022	0.00213	CcSEcCtD
Roflumilast—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.00022	0.00213	CcSEcCtD
Roflumilast—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000219	0.00212	CcSEcCtD
Roflumilast—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000219	0.00212	CcSEcCtD
Roflumilast—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000219	0.00211	CcSEcCtD
Roflumilast—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000218	0.00211	CcSEcCtD
Roflumilast—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000217	0.0021	CcSEcCtD
Roflumilast—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000211	0.00204	CcSEcCtD
Roflumilast—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.00021	0.00203	CcSEcCtD
Roflumilast—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000207	0.00201	CcSEcCtD
Roflumilast—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000207	0.00201	CcSEcCtD
Roflumilast—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000207	0.00201	CcSEcCtD
Roflumilast—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000203	0.00197	CcSEcCtD
Roflumilast—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000202	0.00195	CcSEcCtD
Roflumilast—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000202	0.00195	CcSEcCtD
Roflumilast—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000198	0.00191	CcSEcCtD
Roflumilast—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000196	0.0019	CcSEcCtD
Roflumilast—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000193	0.00186	CcSEcCtD
Roflumilast—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000193	0.00186	CcSEcCtD
Roflumilast—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000191	0.00185	CcSEcCtD
Roflumilast—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000189	0.00183	CcSEcCtD
Roflumilast—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000186	0.0018	CcSEcCtD
Roflumilast—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000186	0.0018	CcSEcCtD
Roflumilast—PDE4C—G alpha (s) signalling events—ADRB2—chronic obstructive pulmonary disease	0.000186	0.0169	CbGpPWpGaD
Roflumilast—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000182	0.00176	CcSEcCtD
Roflumilast—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000182	0.00176	CcSEcCtD
Roflumilast—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000179	0.00173	CcSEcCtD
Roflumilast—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000179	0.00173	CcSEcCtD
Roflumilast—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000178	0.00172	CcSEcCtD
Roflumilast—Rash—Formoterol—chronic obstructive pulmonary disease	0.000178	0.00172	CcSEcCtD
Roflumilast—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000177	0.00172	CcSEcCtD
Roflumilast—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000177	0.00172	CcSEcCtD
Roflumilast—Headache—Formoterol—chronic obstructive pulmonary disease	0.000176	0.00171	CcSEcCtD
Roflumilast—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000176	0.00171	CcSEcCtD
Roflumilast—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000176	0.00171	CcSEcCtD
Roflumilast—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000176	0.0017	CcSEcCtD
Roflumilast—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000175	0.0017	CcSEcCtD
Roflumilast—Rash—Montelukast—chronic obstructive pulmonary disease	0.000174	0.00168	CcSEcCtD
Roflumilast—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000174	0.00168	CcSEcCtD
Roflumilast—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000173	0.00168	CcSEcCtD
Roflumilast—Depression—Prednisone—chronic obstructive pulmonary disease	0.000173	0.00168	CcSEcCtD
Roflumilast—Headache—Montelukast—chronic obstructive pulmonary disease	0.000173	0.00167	CcSEcCtD
Roflumilast—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000171	0.00165	CcSEcCtD
Roflumilast—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000169	0.00164	CcSEcCtD
Roflumilast—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000168	0.00163	CcSEcCtD
Roflumilast—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000168	0.00162	CcSEcCtD
Roflumilast—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000168	0.00162	CcSEcCtD
Roflumilast—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000167	0.00162	CcSEcCtD
Roflumilast—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000167	0.00162	CcSEcCtD
Roflumilast—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000167	0.00162	CcSEcCtD
Roflumilast—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000167	0.00161	CcSEcCtD
Roflumilast—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000164	0.00159	CcSEcCtD
Roflumilast—PDE4D—G alpha (s) signalling events—ADRB2—chronic obstructive pulmonary disease	0.000162	0.0147	CbGpPWpGaD
Roflumilast—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000158	0.00153	CcSEcCtD
Roflumilast—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000157	0.00152	CcSEcCtD
Roflumilast—PDE4A—G alpha (s) signalling events—ADRB2—chronic obstructive pulmonary disease	0.000154	0.014	CbGpPWpGaD
Roflumilast—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000153	0.00148	CcSEcCtD
Roflumilast—PDE4B—G alpha (s) signalling events—ADRB2—chronic obstructive pulmonary disease	0.000143	0.013	CbGpPWpGaD
Roflumilast—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000141	0.00136	CcSEcCtD
Roflumilast—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000138	0.00133	CcSEcCtD
Roflumilast—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000137	0.00132	CcSEcCtD
Roflumilast—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000136	0.00131	CcSEcCtD
Roflumilast—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000126	0.00122	CcSEcCtD
Roflumilast—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000126	0.00122	CcSEcCtD
Roflumilast—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000124	0.0012	CcSEcCtD
Roflumilast—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000122	0.00118	CcSEcCtD
Roflumilast—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.000122	0.00118	CcSEcCtD
Roflumilast—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000121	0.00117	CcSEcCtD
Roflumilast—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000116	0.00112	CcSEcCtD
Roflumilast—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000115	0.00111	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000115	0.00111	CcSEcCtD
Roflumilast—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000114	0.00111	CcSEcCtD
Roflumilast—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000112	0.00109	CcSEcCtD
Roflumilast—Infection—Prednisone—chronic obstructive pulmonary disease	0.00011	0.00107	CcSEcCtD
Roflumilast—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000109	0.00105	CcSEcCtD
Roflumilast—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000108	0.00104	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000101	0.000977	CcSEcCtD
Roflumilast—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000101	0.000976	CcSEcCtD
Roflumilast—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.0001	0.00097	CcSEcCtD
Roflumilast—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	9.75e-05	0.000944	CcSEcCtD
Roflumilast—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	9.63e-05	0.000932	CcSEcCtD
Roflumilast—Rash—Prednisolone—chronic obstructive pulmonary disease	9.61e-05	0.00093	CcSEcCtD
Roflumilast—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	9.61e-05	0.000929	CcSEcCtD
Roflumilast—Fatigue—Prednisone—chronic obstructive pulmonary disease	9.55e-05	0.000924	CcSEcCtD
Roflumilast—Headache—Prednisolone—chronic obstructive pulmonary disease	9.55e-05	0.000924	CcSEcCtD
Roflumilast—Constipation—Prednisone—chronic obstructive pulmonary disease	9.48e-05	0.000917	CcSEcCtD
Roflumilast—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	9.13e-05	0.000884	CcSEcCtD
Roflumilast—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	9.06e-05	0.000877	CcSEcCtD
Roflumilast—Nausea—Prednisolone—chronic obstructive pulmonary disease	9.06e-05	0.000876	CcSEcCtD
Roflumilast—PDE4C—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	8.83e-05	0.00802	CbGpPWpGaD
Roflumilast—Urticaria—Prednisone—chronic obstructive pulmonary disease	8.8e-05	0.000852	CcSEcCtD
Roflumilast—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	8.76e-05	0.000848	CcSEcCtD
Roflumilast—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	8.16e-05	0.00079	CcSEcCtD
Roflumilast—Asthenia—Prednisone—chronic obstructive pulmonary disease	7.95e-05	0.000769	CcSEcCtD
Roflumilast—PDE4D—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	7.68e-05	0.00698	CbGpPWpGaD
Roflumilast—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	7.58e-05	0.000734	CcSEcCtD
Roflumilast—PDE4C—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	7.55e-05	0.00686	CbGpPWpGaD
Roflumilast—PDE4D—Myometrial Relaxation and Contraction Pathways—NOS3—chronic obstructive pulmonary disease	7.38e-05	0.00671	CbGpPWpGaD
Roflumilast—Dizziness—Prednisone—chronic obstructive pulmonary disease	7.33e-05	0.000709	CcSEcCtD
Roflumilast—PDE4A—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	7.31e-05	0.00664	CbGpPWpGaD
Roflumilast—Vomiting—Prednisone—chronic obstructive pulmonary disease	7.04e-05	0.000682	CcSEcCtD
Roflumilast—Rash—Prednisone—chronic obstructive pulmonary disease	6.99e-05	0.000676	CcSEcCtD
Roflumilast—Dermatitis—Prednisone—chronic obstructive pulmonary disease	6.98e-05	0.000675	CcSEcCtD
Roflumilast—Headache—Prednisone—chronic obstructive pulmonary disease	6.94e-05	0.000672	CcSEcCtD
Roflumilast—PDE4C—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	6.86e-05	0.00623	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	6.77e-05	0.00615	CbGpPWpGaD
Roflumilast—Nausea—Prednisone—chronic obstructive pulmonary disease	6.58e-05	0.000637	CcSEcCtD
Roflumilast—PDE4D—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	6.58e-05	0.00597	CbGpPWpGaD
Roflumilast—PDE4B—Myometrial Relaxation and Contraction Pathways—NOS3—chronic obstructive pulmonary disease	6.5e-05	0.00591	CbGpPWpGaD
Roflumilast—PDE4D—Myometrial Relaxation and Contraction Pathways—IL1B—chronic obstructive pulmonary disease	6.28e-05	0.00571	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	6.09e-05	0.00553	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	5.97e-05	0.00543	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	5.79e-05	0.00526	CbGpPWpGaD
Roflumilast—PDE4B—Myometrial Relaxation and Contraction Pathways—IL1B—chronic obstructive pulmonary disease	5.53e-05	0.00503	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	5.53e-05	0.00502	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	5.35e-05	0.00486	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	5.3e-05	0.00482	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	5.26e-05	0.00478	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	5.05e-05	0.00458	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	4.81e-05	0.00437	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	4.67e-05	0.00424	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	4.65e-05	0.00423	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	4.58e-05	0.00416	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	4.43e-05	0.00403	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	4.24e-05	0.00385	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	4.1e-05	0.00372	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	4.05e-05	0.00368	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.82e-05	0.00347	CbGpPWpGaD
Roflumilast—PDE4D—Myometrial Relaxation and Contraction Pathways—IL6—chronic obstructive pulmonary disease	3.68e-05	0.00334	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.53e-05	0.0032	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.47e-05	0.00315	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.41e-05	0.0031	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.33e-05	0.00302	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.27e-05	0.00297	CbGpPWpGaD
Roflumilast—PDE4B—Myometrial Relaxation and Contraction Pathways—IL6—chronic obstructive pulmonary disease	3.24e-05	0.00294	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.16e-05	0.00288	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.11e-05	0.00282	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	3.1e-05	0.00282	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.02e-05	0.00274	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.99e-05	0.00271	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.97e-05	0.0027	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.93e-05	0.00266	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.87e-05	0.00261	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.84e-05	0.00258	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.83e-05	0.00257	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.71e-05	0.00246	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.71e-05	0.00246	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.7e-05	0.00245	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.66e-05	0.00242	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.62e-05	0.00238	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.6e-05	0.00236	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.57e-05	0.00233	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.5e-05	0.00228	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.47e-05	0.00225	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.39e-05	0.00217	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.38e-05	0.00216	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.36e-05	0.00214	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.29e-05	0.00208	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.25e-05	0.00204	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.22e-05	0.00202	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.08e-05	0.00189	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.08e-05	0.00189	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.05e-05	0.00186	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.98e-05	0.0018	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.93e-05	0.00176	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.84e-05	0.00168	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.84e-05	0.00167	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.83e-05	0.00166	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.83e-05	0.00166	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.78e-05	0.00162	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.7e-05	0.00155	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.7e-05	0.00154	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.68e-05	0.00152	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.66e-05	0.00151	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.61e-05	0.00146	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.6e-05	0.00146	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.59e-05	0.00145	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.57e-05	0.00143	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.53e-05	0.00139	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.52e-05	0.00138	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.49e-05	0.00135	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.46e-05	0.00132	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.45e-05	0.00132	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.41e-05	0.00128	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.4e-05	0.00128	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.39e-05	0.00127	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.39e-05	0.00126	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.38e-05	0.00125	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.33e-05	0.00121	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.3e-05	0.00118	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.28e-05	0.00117	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.28e-05	0.00116	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.23e-05	0.00112	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.23e-05	0.00112	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.22e-05	0.00111	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.17e-05	0.00106	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.14e-05	0.00104	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.12e-05	0.00101	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.07e-05	0.000968	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.02e-05	0.000924	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.01e-05	0.000922	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	9.9e-06	0.000899	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	9.71e-06	0.000882	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	9.68e-06	0.00088	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	9.41e-06	0.000855	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	9.39e-06	0.000853	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	9.24e-06	0.00084	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	8.96e-06	0.000814	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.95e-06	0.000813	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	8.61e-06	0.000783	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	8.55e-06	0.000777	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	8.2e-06	0.000745	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	8.19e-06	0.000744	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	8.04e-06	0.00073	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	7.8e-06	0.000708	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.79e-06	0.000708	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7.59e-06	0.000689	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.42e-06	0.000674	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.38e-06	0.00067	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	7.23e-06	0.000657	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	7.21e-06	0.000655	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7e-06	0.000636	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.86e-06	0.000623	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.66e-06	0.000605	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.42e-06	0.000583	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.3e-06	0.000572	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.16e-06	0.00056	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.11e-06	0.000555	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TP53—chronic obstructive pulmonary disease	6.07e-06	0.000552	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.99e-06	0.000545	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.66e-06	0.000514	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.56e-06	0.000505	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.55e-06	0.000504	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.29e-06	0.00048	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.03e-06	0.000457	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.84e-06	0.00044	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.66e-06	0.000423	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.61e-06	0.000418	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.26e-06	0.000387	CbGpPWpGaD
